-Man-Fung Yuen Researcher Activity Profile

Research Author Detailed Information 

Man-Fung Yuen Publication Rate By Year

Man-Fung Yuen has published 2 paper(s) in 2006, 18 paper(s) in 2007, 6 paper(s) in 2008, for a total of 26 research publications in total.

Man-Fung Mf Yuen Author Information

LAST NAME: yuen

FIRST NAME: Man-Fung

INITIALS: mf

AFFILIATION:

Papers

Man-Fung Yuen's Publication Record

1. Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. Year Published: 2006
Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
2. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Year Published: 2006
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho, Nagoya 467-8601, Japan.
3. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Year Published: 2007
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
4. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Year Published: 2007
Department of Medicine, University of Hong Kong, Kong Kong.
5. The natural history of chronic hepatitis B. Year Published: 2007
Department of Medicine, The University of Hong Kong, Hong Kong. hrmelcl@hkucc.hku.hk
6. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. Year Published: 2007
Innogenetics NV, Industriepark Zwijnaarde 7/4, B-9052, Ghent, Belgium.
7. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China.
8. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Year Published: 2007
Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
9. Evolution of Primary and Compensatory Lamivudine Resistance Mutations in Chronic Hepatitis B Virus-Infected Patients during Long-Term Lamivudine Treatment, Assessed by a Line Probe Assay. Year Published: 2007
Innogenetics N.V., Industriepark Zwijnaarde 7/4, B-9052 Ghent, Belgium. fred_shapiro@innogenetics.com.
10. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China. mfyuen@hkucc.hku.hk.
11. Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, PR China.
12. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Year Published: 2007
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
13. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong. mfyuen@hkucc.hku.hk
14. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Year Published: 2007
Department of Medicine, University of Hong Kong, Kong Kong.
15. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Year Published: 2007
Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
16. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. Year Published: 2007
Innogenetics NV, Industriepark Zwijnaarde 7/4, B-9052, Ghent, Belgium.
17. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China.
18. Regulation of XAF1 expression in human colon cancer cell by interferon beta: Activation by the transcription regulator STAT1. Year Published: 2008
Division of Gastroenterology, Ruijin Hospital, Department of Medicine, The Shanghai Jiao Tong University, PR China; Department of Medicine, The University of Hong Kong, Hong Kong, China.
19. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong. mfyuen@hkucc.hku.hk
20. Decreasing trend of esophageal adenocarcinoma in Hong Kong. Year Published: 2007
Department of Medicine, University of Hong Kong, Hong Kong.
21. Effects of aspirin on the development of Helicobacter pylori-induced gastric inflammation and heterotopic proliferative glands in Mongolian gerbils. Year Published: 2008
Department of Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
22. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Year Published: 2008
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
23. The natural history of chronic hepatitis B. Year Published: 2007
Department of Medicine, The University of Hong Kong, Hong Kong. hrmelcl@hkucc.hku.hk
24. Regulation of XAF1 expression in human colon cancer cell by interferon beta: activation by the transcription regulator STAT1. Year Published: 2008
Division of Gastroenterology, Ruijin Hospital, Department of Medicine, The Shanghai Jiao Tong University, PR China.
25. What is the best end point for hepatitis B treatment? Year Published: 2008
the University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
26. What is the best end point for hepatitis B treatment? Year Published: 2008